期刊文献+

益气扶正法治疗脓毒症30例临床观察及其对炎症反应的影响 被引量:11

Clinical Efficacy of Benefiting Qi for Strengthening Resistance on Sepsis and Inflammatory Reaction:A Clinical Observation of 30 Cases
下载PDF
导出
摘要 目的:观察益气扶正中药制剂黄芪注射液对脓毒症的临床疗效以及对血清炎症因子水平的影响。方法:将30例脓毒症患者随机分为治疗组和对照组各30例,治疗组采用西医常规治疗加黄芪注射液治疗;对照组采用西医常规治疗,疗程7 d,分别比较治疗前后中医症状积分、APACHEⅡ评分以及外周静脉血IL-6、IL-10、CRP、PCT等水平的变化。结果:治疗后2组中医疗效比较,差异有统计学意义(P<0.05);两组患者治疗前后气虚症状积分比较,差异有统计学意义(P<0.05);治疗后2组患者的IL-6和CRP水平均降低(P<0.05),治疗组优于对照组,差异有统计学意义(P<0.05)。结论:益气扶正法能提高脓毒症患者的中医临床疗效,可调节IL-6和CRP水平,抑制过度炎症反应。 Objective: To observe the clinical efficacy of Benefiting Qi for Strengthening Resistance in the treatment of sepsis and effect on serum inflammatory factor levels.Methods: Sixty cases of sepsis patients were randomly divided into treatment and control groups,30 cases in each group.Patients were treated with conventional western medical treatment plus Astragalus injection in treatment group and conventional western medicine treatment in control group,with the course of 7 days.TCM symptoms score,APACHE Ⅱ score,as well as peripheral blood IL-6,IL-10,CRP and PCT levels in the two groups were compared before and after treatment.Results: Differences of TCM therapeutic effect is statistically significant between two groups(P 0.05).Differences of Qi deficiency symptoms score are statistically significant between two groups before and after treatment(P0.05).Serum level of IL-6 and CRP decreased in the two groups after treatment(P0.05),and the treatment group was better than the control group,Differences are statistically significant(P 0.05).Conclusion: Benefiting Qi for Strengthening Resistance can improve the clinical efficacy of sepsis,regulate IL-6 and CRP levels and inhibit excessive inflammatory response.
机构地区 广东省中医院
出处 《中医药导报》 2013年第8期26-28,31,共4页 Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金 广东省中医药局科技项目(NO.20121191)
关键词 脓毒症 益气扶正法 炎症反应 中西医结合疗法 Sepsis Benefiting Qi for strengthening resistance Inflammatory reaction Treatment of combination of TCM and western medicine
  • 相关文献

参考文献9

  • 1Bone RC, Balk RA, Cerra FB, et al.Definitions for sep- sis and organ failure and guidelines for the use of inno- vative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physi- cians/Society of Critical Care Medicine [J].Chest, 1992 Jun;101 (6): 1644-55.
  • 2Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ES- ICM/ACCP/ATS/SIS International Sepsis Definitions Con-ference[J].Crit Care Med,2003,31(4):1250-1256.
  • 3无.脓毒症的定义、诊断标准、中医证候诊断要点及说明(草案)[J].中华急诊医学杂志,2007,16(8):797-798. 被引量:269
  • 4Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 [J]. Intensive Care Med, 2013 Feb;39(2):165-228.
  • 5Knaus WA, Draper EA, Wagner DP, et al. APACHE II :a severity of disease classification system [J].Crit Care Med,1985,13(10): 818-829.
  • 6陈健,房志仲.黄芪注射液的药理作用及临床应用[J].天津医科大学学报,2005,11(1):153-157. 被引量:42
  • 7Memis D, Gursoy O, Tasdogan M,et al. High C-reactive protein and low cholesterol levels are prognostic markers of survival in severe sepsis [J]. Journal of Clinical Anes- thesia, 2007,19(3):186-191.
  • 8Latifi SQ, O'Riordan MA, Levine AD,et al. Persistent E levation of Serum Interleukin-6 in Intra abdominal Sep- sis Identifies Those With Prolonged Length of Stay[J].J Pediatr Surg. 2004,39(10):1548-52.
  • 9Seumpia PO,Moldawer LL.Biology of interleukin-lO and its regulatory roles in sepsis syndromes [J].Crit Care Med,2005,33(12 Suppl):S468-71.

二级参考文献25

共引文献309

同被引文献141

引证文献11

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部